Looking to expand its footprint in the booming glucagon-like peptide (GLP-1) market, Danish drugmaker Novo Nordisk has ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Novo Nordisk says it is taking a flexible portfolio approach and plans to price the injectable semaglutide close to Wegovy’s ...

Ozempic, which is injected once a week under careful medical supervision, is said to help control diabetes and help Type 2 ...

Semaglutide, a GLP-1 receptor agonist (RA), was associated with a significantly lower risk for adult-onset epilepsy in patients with diabetes than other glucose-lowering drugs (GLDs). Notably, this ...

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

Novo Nordisk's appeal was listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla ...

GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

Novo Nordisk has approached the Delhi High Court to prevent Dr Reddy’s Laboratories from manufacturing and exporting ...

Ozempic (injectable semaglutide) is a once-weekly treatment indicated as an add-on to diet and exercise for adults with uncontrolled Type 2 diabetes mellitus (T2DM).

Novo Nordisk has officially launched Ozempic in India for diabetes care. Here's how the injectable works, its dosage options, ...